Skip to main content

Advertisement

Table 4 Therapy of the 89 malaria patients during January 2013–June 2017

From: High prevalence of malaria in a non-endemic setting: comparison of diagnostic tools and patient outcome during a four-year survey (2013–2017)

Parasitaemia range Malaria species Therapy Follow-up (parasitaemia reduction up to 0.001%)
24 h 48 h 72 h > 72 h
< 0.001–< 1% 40 Pf 12 Quininea 1 1 1
8 Atovaquone + proguanil 1
14 Mefloquine 5 3 1
6 Piperaquine tetraphosphate + dihydroartemisinin   1
  2 Pv 1 Chlorochine + primaquine
1 Chlorochine + ceftriaxone
  9 Po 3 Mefloquine 2
1 Quinine
1 Chlorochine + primaquine
1 Quinine + doxycycline + primaquine 1d
1 Piperaquine tetraphosphate + dihydroartemisinin
2 unknown
  1 Pm 1 Atovaquone + proguanil 1
  1 Pf + Po 1 Atovaquone + proguanil + primaquine
  1 Pf + Pm 1 Piperaquine tetraphosphate + dihydroartemisinin
1–10% 32 Pf 15 Quinineb 3 3 4
  9 Mefloquine 1 2
4 Atovaquone + proguanil 1 2
4 Piperaquine tetraphosphate + dihydroartemisinin 2
> 10% negative 1 Pf 1 Quinine 1
2 Pf 2 Untreatedc
  1. –: no cases
  2. a6 out of 12 were in association with doxycycline; b 5 out of 15 were in association with clindamycine, doxycycline, ampicillin + sulbactam or ceftriaxone; c in these cases, according to the Italian Ministry of Health guidelines, no therapy was administered because microscopy was negative; d a full negativization was obtained in this case